1. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117–71.
2. Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, DuGar B, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. NATURE. 2011;472(7341):57–63.
3. Tang WHW, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X, et al. Intestinal Microbial Metabolism of Phosphatidylcholine and Cardiovascular Risk. N Engl J Med. 2013;368(17):1575–84.
4. Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med. 2013;19(5):576–85.
5. Ierardi E, Sorrentino C, Principi M, Giorgio F, Losurdo G, Di Leo A. Intestinal microbial metabolism of phosphatidylcholine: a novel insight in the cardiovascular risk scenario. Hepatobiliary Surg Nutr. 2015;4(4):289–92.
6. Tang WH, Wang Z, Shrestha K, Borowski AG, Wu Y, Troughton RW, et al. Intestinal microbiota-dependent phosphatidylcholine metabolites, diastolic dysfunction, and adverse clinical outcomes in chronic systolic heart failure. J Card Fail. 2015;21(2):91–6.
7. Li XS, Obeid S, Klingenberg R, Gencer B, Mach Fo, Räber L, et al. Gut microbiota-dependent trimethylamine N-oxide in acute coronary syndromes: a prognostic marker for incident cardiovascular events beyond traditional risk factors. Eur Heart J. 2017;38(11):814–24.
8. Heianza Y, Ma W, Manson JE, Rexrode KM, Qi LJJotAHAC, Disease C. Gut Microbiota Metabolites and Risk of Major Adverse Cardiovascular Disease Events and Death: A Systematic Review and Meta-Analysis of Prospective Studies. Journal of the American Heart Association. 2017;6(7):e004947.
9. Schiattarella GG, Sannino A, Toscano E, Giugliano G, Gargiulo G, Franzone A, et al. Gut microbe-generated metabolite trimethylamine-N-oxide as cardiovascular risk biomarker: a systematic review and dose-response meta-analysis. 2017;38(39).
10. Heianza Y, Ma W, Manson JE, Rexrode KM, Qi L. Gut Microbiota Metabolites and Risk of Major Adverse Cardiovascular Disease Events and Death: A Systematic Review and Meta-Analysis of Prospective Studies. Journal of the American Heart Association. 2017;6(7):e004947.
11. Roffi M, Patrono C, Collet J-P, Mueller C, Valgimigli M, Andreotti F, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3):267–315.
12. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2017;39(2):119–77.
13. Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. The American journal of cardiology. 1983;51(3):606.
14. Patel RS, Su S, Neeland IJ, Ahuja A, Veledar E, Zhao J, et al. The chromosome 9p21 risk locus is associated with angiographic severity and progression of coronary artery disease. Eur Heart J. 2010;31(24):3017–23.
15. Beasley TM, Erickson S, Allison DB. Rank-based inverse normal transformations are increasingly used, but are they merited? Behavior genetics. 2009;39(5):580–95.
16. Yan J, Winter LB, Burns-Whitmore B, Vermeylen F, Caudill MA. Plasma choline metabolites associate with metabolic stress among young overweight men in a genotype-specific manner. Nutrition Diabetes. 2012;2(10):e49.
17. Yu E, Rimm E, Qi L, Rexrode K, Albert CM, Sun Q, et al. Diet, Lifestyle, Biomarkers, Genetic Factors, and Risk of Cardiovascular Disease in the Nurses' Health Studies. Am J Public Health. 2016;106(9):1616–23.
18. Brown JM, Hazen SL. The gut microbial endocrine organ: bacterially derived signals driving cardiometabolic diseases. Annu Rev Med. 2015;66:343–59.
19. Tang WHW, Hazen SL. The contributory role of gut microbiota in cardiovascular disease. J Clin Investig. 2014;124(10):4204–11.
20. Wang Z, Roberts AB, Buffa JA, Levison BS, Zhu W, Org E, et al. Non-lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of Atherosclerosis. Cell. 2015;163(7):1585–95.
21. Wang Z, Bergeron N, Levison BS, Li XS, Chiu S, Jia X, et al. Impact of chronic dietary red meat, white meat, or non-meat protein on trimethylamine N-oxide metabolism and renal excretion in healthy men and women. Eur Heart J. 2019;40(7):583–94.
22. Senthong V, Wang Z, Fan Y, Wu Y, Tang WHWJJotAHA. Trimethylamine N ãxide and Mortality Risk in Patients With Peripheral Artery Disease. Journal of the American Heart Association. 2016;5(10):e004237.
23. Guasch-Ferré M, Hu FB, Ruiz‐Canela M, Bulló M, Toledo E, Wang DD, et al. Plasma Metabolites From Choline Pathway and Risk of Cardiovascular Disease in the PREDIMED (Prevention With Mediterranean Diet) Study. Journal of the American Heart Association. 2017;6(11):e006524.
24. Sheng Z, Tan Y, Liu C, Zhou P, Li J, Zhou J, et al. Relation of Circulating Trimethylamine N-Oxide With Coronary Atherosclerotic Burden in Patients With ST-segment Elevation Myocardial Infarction. The American journal of cardiology. 2019;123(6):894–8.
25. Landfald B, Valeur J, Berstad A, Raa, JJMEiH. Disease. Microbial trimethylamine-N-oxide as a disease marker: something fishy? Microbial Ecology in Health and Disease. 2017;28(1).
26. Shafi T, Powe NR, Meyer TW, Hwang S, Hai X, Melamed ML, et al. Trimethylamine-Oxide and Cardiovascular Events in Hemodialysis Patients. J Am Soc Nephrol. 2017;28(1):321.
27. Jia J, Dou P, Gao M, Kong X, Li C, Liu Z, et al. Assessment of Causal Direction Between Gut Microbiota–Dependent Metabolites and Cardiometabolic Health: A Bidirectional Mendelian Randomization Analysis. Diabetes. 2019;68(9):1747.
28. Katie M, Jonathan S. Dietary Choline and Betaine and Risk of CVD: A Systematic Review and Meta-Analysis of Prospective Studies. Nutrients. 2017;9(7):711-.
29. Millard HR, Musani SK, Dibaba DT, Talegawkar SA, Taylor HA, Tucker KL, et al. Dietary choline and betaine; associations with subclinical markers of cardiovascular disease risk and incidence of CVD, coronary heart disease and stroke: the Jackson Heart Study. Eur J Nutr. 2018;57(1):51–60.
30. Lever M, George PM, Elmslie JL, Atkinson W, Slow S, Molyneux SL, et al. Betaine and Secondary Events in an Acute Coronary Syndrome Cohort. PLOS ONE. 2012;7(5):e37883.
31. Lever M, George PM, Atkinson W, Molyneux SL, Elmslie JL, Slow S, et al. Plasma Lipids and Betaine Are Related in an Acute Coronary Syndrome Cohort. PLOS ONE. 2011;6(7):e21666.
32. Ueland PM. Choline and betaine in health and disease. J Inherit Metab Dis. 2011;34(1):3–15.
33. Nagata C, Wada K, Tamura T, Konishi K, Kawachi T, Tsuji M, et al. Choline and Betaine Intakes Are Not Associated with Cardiovascular Disease Mortality Risk in Japanese Men and Women. J Nutr. 2015;145(8):1787–92.